Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025)

Quarterly Current Deferred Revenue rose 2880.4% to $11.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, up 2880.4% year-over-year, with the annual reading at $11.9 million for FY2025, 2880.4% up from the prior year.

Lyra Therapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $11.9 million for Q4 2025.

  • Current Deferred Revenue came in at $11.9 million for Q4 2025, roughly flat from $11.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $14.9 million in Q1 2023 to a low of $216000.0 in Q1 2025.
  • The 5-year median for Current Deferred Revenue is $2.5 million (2022), against an average of $5.9 million.
  • Year-over-year, Current Deferred Revenue plummeted 91.17% in 2024 and then soared 2880.4% in 2025.
  • Lyra Therapeutics' Current Deferred Revenue stood at $11.7 million in 2021, then crashed by 89.12% to $1.3 million in 2022, then surged by 30.04% to $1.7 million in 2023, then plummeted by 76.0% to $398000.0 in 2024, then skyrocketed by 2880.4% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Current Deferred Revenue are $11.9 million (Q4 2025), $11.9 million (Q3 2025), and $11.9 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Lyra Therapeutics - - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 11.86 Mn
Sep 30, 2025 11.87 Mn
Jun 30, 2025 11.89 Mn
Mar 31, 2025 216,000.00
Dec 31, 2024 398,000.00
Sep 30, 2024 607,000.00
Jun 30, 2024 814,000.00
Mar 31, 2024 1.32 Mn
Dec 31, 2023 1.66 Mn
Sep 30, 2023 1.73 Mn
Jun 30, 2023 1.50 Mn
Mar 31, 2023 14.94 Mn
Dec 31, 2022 1.28 Mn
Sep 30, 2022 2.73 Mn
Jun 30, 2022 2.55 Mn
Mar 31, 2022 14.22 Mn
Dec 31, 2021 11.72 Mn
Sep 30, 2021 8.30 Mn
Jun 30, 2021 12.00 Mn